Cited by 1,180Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Research Studies

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Open access

Wakelee, Heather, Liberman, Moishe, Kato, Terufumi, Tsuboi, Masahiro, Lee, Se-Hoon, Gao, Shugeng, Chen, Ke-Neng, Dooms, Christophe, Majem, Margarita, Eigendorff, Ekkehard, Martinengo, Gastón L., Bylicki, Olivier, Rodríguez-Abreu, Delvys, Chaft, Jamie E., Novello, Silvia, Yang, Jing, Keller, Steven M., Samkari, Ayman, Spicer, Jonathan D.·2023·New England Journal of Medicine

DOI 10.1056/nejmoa2302983PMC PMC11074923

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone. METHODS: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles. The dual primary end points were event-free survival (the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence, or death) and overall survival. Secondary end points included major pathological response, pathological complete response, and safety. RESULTS: A total of 397 participants were assigned to the pembrolizumab group, and 400 to the placebo group. At the prespecified first interim analysis, the median follow-up was 25.2 months. Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001). The estimated 24-month overall survival was 80.9% in the pembrolizumab group and 77.6% in the placebo group (P = 0.02, which did not meet the significance criterion). A major pathological response occurred in 30.2% of the participants in the pembrolizumab group and in 11.0% of those in the placebo group (difference, 19.2 percentage points; 95% CI, 13.9 to 24.7; P<0.0001; threshold, P = 0.0001), and a pathological complete response occurred in 18.1% and 4.0%, respectively (difference, 14.2 percentage points; 95% CI, 10.1 to 18.7; P<0.0001; threshold, P = 0.0001). Across all treatment phases, 44.9% of the participants in the pembrolizumab group and 37.3% of those in the placebo group had treatment-related adverse events of grade 3 or higher, including 1.0% and 0.8%, respectively, who had grade 5 events. CONCLUSIONS: Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2302983

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citation
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citation
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citation
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Self-citation
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citation
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citation
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430

Show all 18 references

Research works printed but not linked: 2

Brierly JD Gospodarowicz MK Wittekind C. TNM classification of malignant tumors. 8th ed. New York: John Wiley 2016.
Heymach JV Harpole D Mitsudomi T et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. In: Proceedings and Abstracts of the 114th Annual Meeting of the American Association for Cancer Research April 14–19 2023. Orlando FL: American Association for Cancer Research 2023. abstract.

Sorted by citations

Items 201–300 of 1,000

Current perspective on resectability in stage III locally advanced NSCLC – The thoracic surgeons’ view
Aigner, C., Baldes, N., Begic, M., Doerr, F., Hoda, M. A., & Bölükbas, S. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115426 · Cited by 12
Targeting myeloid cell immunometabolism to improve current non-small cell lung cancer therapies
Runtsch, M. C., Angiari, S., & Kargl, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108893 · Cited by 12
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Schmid, S., Dimopoulou, G., Schil, P. E. V., König, D., Mauti, L. A., Itchins, M., Früh, M., Oselin, K., Landi, L. M., Pérol, M., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108635 · Cited by 12
Recent advances and challenges of cellular immunotherapies in lung cancer treatment
Yang, C., Liu, Y., Huang, Z., Liu, S., Zhang, X., Liu, Q., & Dai, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00679-8 · Cited by 13
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
Sanber, K. S., Rosner, S., Forde, P. M., & Marrone, K. A. (2023) · BioDrugs · doi:10.1007/s40259-023-00614-5 · Cited by 13
Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?
Inoue, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-63 · Cited by 12
Interrogating the roles of lymph node metastasis in systemic immune surveillance
Basto, P. A., & Reticker-Flynn, N. E. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10261-3 · Cited by 11
Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review
Li, J., Luo, Z., Jiang, S., & Li, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112200 · Cited by 12
A novel CAF-cancer cell crosstalk-related gene prognostic index based on machine learning: prognostic significance and prediction of therapeutic response in head and neck squamous cell carcinoma
Xu, Y., Li, J., Wang, J., & Deng, F. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05447-6 · Cited by 12
Adaptive radiation strategy with V20 limitation associates with survival benefit and lower incidence of symptomatic radiation pneumonitis in stage III NSCLC patients receiving concurrent immunotherapy and thoracic radiation
Song, Z., Zhang, X., Ma, Y., Ma, S., Feng, Z., & Liu, X. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102184 · Cited by 11
Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Zhang, Q., Duan, J., Zhang, Y., Yang, L., & Li, D. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02767-6 · Cited by 11
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Barcellini, L., Nardin, S., Sacco, G., Ferrante, M., Rossi, G., Barletta, G., Bennicelli, E., Dellepiane, C., Tagliamento, M., Pollone, B. R., et al. (2025) · Cancers · doi:10.3390/cancers17040652 · Cited by 11
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Wheatley‐Price, P., Navani, V., Pabani, A., Routy, B., Snow, S. L., Denault, M.-H., Kim, Y.-J., Syed, I. A., Devost, N., Hui, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108583 · Cited by 11
Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects
Lü, C., Tufail, M., Jiang, C., & Li, N. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03806-x · Cited by 11
Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study
Motta, L., Molinari, F., Pankovics, J., Pedrazzini, B., Valera, A., Epistolio, S., Giudici, L., Freguia, S., Patella, M., Imbimbo, M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145135 · Cited by 11
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design
Starling, N., Élez, E., Strickler, J. H., Benson, A. B., Oki, E., Mendez, G. A., Ferreiro, R., Lau, Y. L., Kawazoe, A., Tian, M., et al. (2026) · Future Oncology · doi:10.1080/14796694.2025.2606910 · Cited by 11
Global advances and future directions in lung cancer care: expert consensus and strategic priorities
Meyer, M.-L., Peters, S., Janne, P. A., Mok, T. S., Bunn, P. A., Karim, N. A., Altorki, N. K., Arrieta, O., Bar, J., Cappuzzo, F., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106034 · Cited by 12
Self-citation
Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group
Tan, A. C., Liao, B.-C., Li, M., Lee, D. J., Uehara, Y., Thamlikitkul, L., Zhang, J.-T., Zheng, M., Lee, C. K., Pavlakis, N., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103696 · Cited by 11
Self-citation
Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer
Zheng, J., Li, Y., Jin, C. H., Ruan, K., Sun, K., Chen, H., Wang, M., Zhang, S., Zhou, J., & Zhou, J. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107326 · Cited by 11
Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer
Lee‐Mateus, A. Y., Sawal, N., Hartley, C., Edell, E. S., Vierkant, R. A., & Reisenauer, J. S. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.10.003 · Cited by 11
Resection of the Primary Tumor and Survival in Patients with Single-Site Synchronous Oligometastatic Non–Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Database
Rodríguez-Quintero, J. H., Jindani, R., Kamel, M., Zhu, R. C., Vimolratana, M., Chudgar, N. P., & Stiles, B. M. (2024) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001035 · Cited by 11
The Current Achievements of Multi-Gene Panel Tests in Clinical Settings for Patients with Non-Small-Cell Lung Cancer
Sakaguchi, T., Iketani, A., Esumi, S., Esumi, M., Suzuki, Y., Ito, K., Fujiwara, K., Nishii, Y., Katsuta, K., Yasui, H., et al. (2024) · Cancers · doi:10.3390/cancers16091670 · Cited by 11
A scoping review of lung cancer surgery with curative intent: workup, fitness assessment, clinical outcomes
Hardavella, G. F., Carlea, F., Karampinis, I., Patirelis, A., Athanassiadi, K., Lioumpas, D., Rei, J., Mejía, L. H., Benakis, G., Caruana, E. J., et al. (2024) · Breathe · doi:10.1183/20734735.0046-2024 · Cited by 11
Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy
Hashimoto, K., Murakami, Y., Omura, K., Takahashi, H., Suzuki, R., Yoshioka, Y., Oguchi, M., Ichinose, J., Matsuura, Y., Nakao, M., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.010 · Cited by 10
Increased opioid consumption in neoadjuvant immunotherapy plus chemotherapy for patients with non‐small‐cell lung cancer: A multicenter, prospective cohort study
Wang, K., Er, J., Zhang, Y., Song, C., Yu, Y., Gao, R., Xu, H., Dong, X., Yuan, L., Liu, Q., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14893 · Cited by 10
Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer
Fox, A. H., Alexander, M., Forcucci, J. A., & Silvestri, G. A. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.08.006 · Cited by 10
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial
Yu, X., Huang, C., Du, L., Wang, C.-G., Yang, Y., Yu, X., Lin, S., Yang, C., Zhao, H., Cai, S., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102997 · Cited by 10
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings
Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C. C., Izard, S. M., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009301 · Cited by 10
Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Practical Guide of Current Controversies
Phillips, W. J., Jackson, A., Kidane, B., Lim, G., Navani, V., & Wheatley‐Price, P. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.01.006 · Cited by 12
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients
Greib, A., Zhao, S., Ploch, M., Henricks, J., Easterling, R. S., Moodabagil, M., Lopez, G., Li, M., Goodyear, E. G., Sharp, J., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2469375 · Cited by 10
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”
Delcuratolo, M. D., Crespi, V., Saba, G., Mogavero, A., Napoli, V. M., Garbo, E., Cani, M., Ungaro, A., Reale, M. L., Merlini, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102918 · Cited by 10
Self-citation
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Marron, T. U., Luke, J. J., Hoffner, B., Perlmutter, J., Szczepanek, C. M., Anagnostou, V., Silk, A. W., Romero, P. J., Garrett-Mayer, E. S., & Emens, L. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010760 · Cited by 12
Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma
Jiang, J., Feng, K., Zhang, L., & Ma, K. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000086 · Cited by 10
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer
Chandra, R., Ehab, J., Hauptmann, E., Gunturu, N. S., Karalis, J. D., Kent, D. O., Heid, C. A., Reznik, S. I., Sarkaria, I. S., Huang, H., et al. (2025) · Cancers · doi:10.3390/cancers17111732 · Cited by 11
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
Xenophontos, E., Levra, N. G., Durieux, V., van Geffen, W. H., Grisay, G., Alonso, C. D. L. P., Arasanz, H., Prisciandaro, E., Ferrara, R., Derks, J. L., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108671 · Cited by 10
Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017–2025
Evison, M., Ahmed, T., Chitnis, M. M., Ward, R., Netto, D., Cove-Smith, L., Shah, R. N. H., Steele, N. L., Walls, G., West, D., et al. (2025) · Thorax · doi:10.1136/thorax-2025-223096 · Cited by 10
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer
Jones, D. R., Opitz, I., Harpole, D. H., Yanagawa, J., Lim, E. K. S., Tsutani, Y., Tan, D. S.-W., Dacic, S., Ganti, A. K., Bodla, S., et al. (2025) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.09.017 · Cited by 10
Applications of artificial intelligence in non–small cell lung cancer: from precision diagnosis to personalized prognosis and therapy
Chang, L., Li, H., Wu, W., Liu, X., Yan, J., Chen, Z., Wu, H., & Song, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07591-z · Cited by 10
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 11
Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process
Tankel, J., Spicer, J. D., Chu, Q. S.-C., Fiset, P., Kidane, B., Leighl, N. B., Joubert, P., Maziak, D. E., Palma, D. A., McGuire, A., et al. (2023) · Current Oncology · doi:10.3390/curroncol30120755 · Cited by 10
Self-citation
Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis
Wang, H., Liang, S., Yu, Y., & Han, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1276549 · Cited by 10
Defining resectability: When do you try to take it out?
Etienne, H., Battilana, B., Spicer, J. D., Werner, R. S., & Opitz, I. (2024) · JTCVS Open · doi:10.1016/j.xjon.2024.03.012 · Cited by 10
Self-citation
Top advances of the year: Perioperative therapy for lung cancer
Aredo, J. V., & Wakelee, H. A. (2024) · Cancer · doi:10.1002/cncr.35357 · Cited by 10
Self-citation
Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy
Shan, J., Liu, Z., Chen, S., Du, C., Li, B., Ruan, L.-X., Kong, M., Wang, L., Du, M., Shi, S., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03462-4 · Cited by 10
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England
Brunelli, A., Hoffman, R., Wotton, R., Baijal, S., Jain, P., Clarke, K., Escriu, C., Fakih, O., Franks, K., Lodhia, J. V., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.12.010 · Cited by 10
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Saw, S. P. L., Zhong, W., Fu, R., Li, M. S. C., Goto, Y., Fox, S. B., Yatabe, Y., Ong, B., Ng, C. S. H., Lee, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2024.108076 · Cited by 10
Self-citation
Perioperative Immunotherapy in Non-Small Cell Lung Cancer
O'Brien, J. A., & Bodor, J. N. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01160-6 · Cited by 9
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy
Berezowska, S., Keyter, M., Bouchaab, H., & Weissferdt, A. (2024) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000441 · Cited by 10
Early Detection and Interception of Lung Cancer
Chang, A. E. B., Potter, A. L., Yang, C. J., & Sequist, L. V. D. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.004 · Cited by 9
“Percentage” and “size” of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy
Sun, W., Qu, L., Wu, J., Liu, X., Wang, C., Jiang, Y., Liu, Y., Chen, M., Wang, X., & Lin, D. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.05.009 · Cited by 9
Concordance of Whole-Slide Imaging and Conventional Light Microscopy for Assessment of Pathologic Response Following Neoadjuvant Therapy for Lung Cancer
Deutsch, J. S., Wang, D., Chen, K. Y., Cimino‐Mathews, A., Thompson, E. D., Jedrych, J. J., Anders, R. A., Gabrielson, E., Illei, P. B., Uttam, S., et al. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102166 · Cited by 9
Self-citation
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
Zhou, N., Leung, C. H., William, W. N., Weissferdt, A., Pataer, A., Godoy, M. C. B., Carter, B. W., Fossella, F. V., Tsao, A. S., Blumenschein, G. R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009677 · Cited by 9
Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence
Burr, J., Johnson, K. C., Carmicheal, J., Lin, C. H., & Ganti, A. K. (2024) · Cancer Medicine · doi:10.1002/cam4.70402 · Cited by 9
Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Osataphan, S. A., Awidi, M. A., Jan, Y. J., Gunturu, K. S., Sundararaman, S. K., Viray, H., Frankenberger, E., Mariano, M., O’Loughlin, L., Piper‐Vallillo, A. J., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108023 · Cited by 9
Perioperative Treatment in Gastric Cancer: A Fast-Changing Field
Costa, M., Fernandes, C. L., & Magalhães, H. (2024) · Cancers · doi:10.3390/cancers16234036 · Cited by 9
Next-generation immunotherapy: igniting new hope for lung cancer
Li, M. S. C., Chan, A. L. S., Mok, K. K. S., Chan, L. L., & Mok, T. S. K. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241302021 · Cited by 9
Neoadjuvant immunotherapy for non-small cell lung cancer: Opportunities and challenges
Hu, J., Zhang, J., Wan, S., & Zhang, P. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.11.003 · Cited by 9
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non–Small Cell Lung Cancer
Schüler, M. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1441 · Cited by 9
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Zeng, L., Yan, H., Jiang, W., Qin, H., Dai, J., Zhang, Y., Wei, S. N., Chen, S., Liu, L., Xiong, Y., et al. (2025) · Med · doi:10.1016/j.medj.2025.100574 · Cited by 9
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives
Jin, X., Zhao, W., Li, G., & Jiang, J. (2025) · Cancer Control · doi:10.1177/10732748251334434 · Cited by 9
A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma
Zhao, Y., Zhang, L., Xia, L., Haoran, E., Wang, T., Lu, H., Chen, H., She, Y., Tang, H., Wu, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt7682 · Cited by 9
Real‐world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event‐free survival
Cooper, A. J., Garbo, E., Arfè, A., Conroy, M. R., Shaverdian, N., Bott, M. J., Gorría, T., Pecci, F., Aldea, M. D., Anagnostou, V., et al. (2025) · Cancer · doi:10.1002/cncr.70081 · Cited by 9
Self-citation
Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer
Matsumoto, K., Noda, Y., Hachiya, K., Muramatsu, F., Okamoto, N., Jia, W., Shiroyama, T., Mori, M., Tamiya, M., Kinehara, Y., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-025-04161-7 · Cited by 9
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
Chaft, J. E., Sun, Z., Rudin, C. M., Khullar, O. V., Simone, C. B., Oettel, K. R., Kozono, D., Sunkara, R., Faller, B. A., Isbell, J. M., et al. (2026) · JAMA · doi:10.1001/jama.2026.8992 · Cited by 9
Self-citation
Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy
Donington, J. S., Hu, X., Zhang, S., Song, Y., Arunachalam, A., Chirovsky, D. R., Gao, C., Lerner, A., Jiang, A., Signorovitch, J., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.12.006 · Cited by 9
Self-citation
Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis
Mei, T., Zhou, Q., & Gong, Y. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.12.006 · Cited by 9
The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
Güven, D. C., Şahin, T. K., & Kılıçkap, S. (2023) · Cancers · doi:10.3390/cancers16010156 · Cited by 9
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent
Strohbehn, G. W., & Gyawali, B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00857-9 · Cited by 9
Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis
Wallwork, R. S., Kotzin, J. J., Cappelli, L. C., Mecoli, C. A., Bingham, C. O., Wigley, F. M., Wilson, P. C., DiRenzo, D., & Shah, A. A. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152460 · Cited by 9
Surgically resectable nonsmall cell lung cancer: a contemporary approach
D'Amours, M.-F., Wu, F. T. H., Theisen-Lauk, O., Chan, E. K., McGuire, A., & Ho, C. (2024) · European Respiratory Journal · doi:10.1183/13993003.00332-2024 · Cited by 9
Perioperative Nivolumab in Resectable Lung Cancer
Sobrero, S., Vaisitti, F., & Leo, F. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2407267 · Cited by 9
Contemporary Concise Review 2023: Advances in lung cancer and interventional pulmonology
Leong, T. L., & Steinfort, D. (2024) · Respirology · doi:10.1111/resp.14789 · Cited by 8
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
Zhou, B., Zhang, F., Guo, W., Wang, S., Li, N., Qiu, B., Zhao, L., Li, J., Shao, K., Xue, Q., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009355 · Cited by 8
Self-citation
Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities
He, X., Yang, Z., Wu, F., Liang, Q., Liu, W., Yu, F., & Chen, C. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107994 · Cited by 8
Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials
de Moraes, F. C. A., Pasqualotto, E., Rodrigues, A. L. S. D. O., & Burbano, R. M. R. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03777-4 · Cited by 8
Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma
Lei, M., Zhang, X., Hu, L., Fu, S., Xiao, M., Long, Z., Zhu, H., Zhou, Y., & Hong, S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108057 · Cited by 8
Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort
Batra, U., Prabhash, K., Noronha, V., Deshpande, R., Khurana, S., Bhat, G. M., Mistry, R., Agarwala, V., Rajpurohit, S., Poladia, B. P., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00353 · Cited by 8
Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer
Hofman, P. M., Christopoulos, P., D’Haene, N., Gosney, J. R., Normanno, N., Schuuring, E. M. D., Tsao, M., Quinn, C. M., Russell, J., Keating, K. E., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108107 · Cited by 8
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
de Marinis, F., Ardizzoni, A., Attili, I., Bonanno, L., Bria, E., Cortinovis, D. L., Margaritora, S., Mazzoni, F., Mercadante, E., Morabito, A., et al. (2025) · Current Oncology · doi:10.3390/curroncol32020110 · Cited by 8
Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study
Qi, Y., Zhai, X., Xu, Q., Jin, Y., Guo, Y., Zhao, M., Zhu, H., & Guo, H. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03961-0 · Cited by 8
Advantages of robotic-assisted thoracic surgery after neoadjuvant therapy in NSCLC: A propensity score–matched analysis
Li, H.-J., Ding, J.-Y., Nie, Q., Hong, H.-Z., Qiu, Z., Fu, R., Zhang, C., Zhang, J., Xu, Z., Yang, J., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110022 · Cited by 8
Self-citation
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
Zhang, C., Wu, P., Li, D., Zhou, J., Lin, C., Gu, X., Shang, D., Ma, R., Liu, J., Zhang, G., et al. (2025) · Med · doi:10.1016/j.medj.2025.100669 · Cited by 8
Prognosis and relapse patterns in patients with non-small cell lung cancer with pathologic complete response after neoadjuvant immunochemotherapy
Fang, Y., Yan, W., Zhao, Z.-R., Jiang, L., Yu, X., Yang, X., Yu, Z., Luo, Q., Long, H., & Chen, K. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2024-2200 · Cited by 8
Self-citation
The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy
Xu, Q., Chu, J., Hu, Q., Sun, Y., Jiang, F., Li, S., & Liu, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104745 · Cited by 8
Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer
Zhao, J., Liu, M., Zhu, C., Li, Z., Liu, Z., Abulizi, D., Liu, S., Wang, X., Yang, H., & Hou, X. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01067-4 · Cited by 9
Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study
Guan, S., Wang, Y., Liu, Q., Yan, M., Ren, K., Wang, J., Bi, N., & Zhao, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591134 · Cited by 8
Machine learning–guided single-cell multiomics uncovers GDF15-driven immunosuppressive niches in NSCLC: A translational framework for overcoming anti-PD-1 resistance
Zhang, X., Yin, Z., Chen, X., Zhang, N., Yu, S., Zhu, C., Zhu, L., Shao, L., Li, B., Jin, R., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102459 · Cited by 8
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting
Zervanos, D.-I., Galatou, E., Miliotou, Α. N., Theodoroula, N. F., Grigoriadis, N., & Vizirianakis, I. S. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030043 · Cited by 8
Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study
Wang, W., He, Y., Yuan, X., Weng, L., Bai, J., Liu, X., Han, L., Xu, J., Wang, S., Lu, S., et al. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0047 · Cited by 8
Self-citation
Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study
Li, G., Liu, C., Xi, P., Hou, L., Xia, Y., Qi, Y., Pan, W., Bai, W., Li, X., Zhou, H., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108883 · Cited by 8
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
Johnson, D. B., Nassar, A. H., Aijaz, A., Knight, A. D., Zerey, M. M., Rini, B. I., Naqash, A. R., & Sullivan, R. J. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01123-4 · Cited by 8
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study
Volpe, S., Zaffaroni, M., Piperno, G., Vincini, M. G., Zerella, M. A., Mastroleo, F., Cattani, F., Fodor, C. I., Bellerba, F., Bonaldi, T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11701-9 · Cited by 8
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
Lai, J., Kuang, X., Fu, Y., & Li, J. (2024) · Immunotherapy · doi:10.2217/imt-2023-0307 · Cited by 8
Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer
Wang, X., Chen, D., Ma, Y., Mo, D., & Yan, F. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03416-5 · Cited by 8
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Ospina, A. V., Nadal, S. B., de la Cruz, J. L. C.-C., González-Larriba, J. L., Vidueira, I. M., Sureda, B. M., Nadal, E., Hernándo, F., Álvarez, A., del Barco, E., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03382-y · Cited by 8
Self-citation
Eradicating gross tumor disease: a prerequisite for efficient radioimmunotherapy?
Deutsch, É., & Lévy, A. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae071 · Cited by 8
Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer
Huang, L., & Petersen, R. H. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107846 · Cited by 8
Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review
Cui, S., Wang, N., Liang, Y., Meng, Y. G., Shu, X., & Kong, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112903 · Cited by 10
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma
Stefanini, B., Manfredi, G. F., D’Alessio, A., Fulgenzi, C. A. M., Awosika, N. O., Celsa, C., Pirisi, M., Rigamonti, C., Burlone, M. E., Vincenzi, F., et al. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2419519 · Cited by 8
Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis
Ay, L., Steiner, D., Fabikan, H., Illini, O., Krenbek, D., Klikovits, T., Benej, M., Kirchbacher, K., Watzka, S., Valipour, A., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107997 · Cited by 8

Authors: Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, O., Rodríguez-Abreu, D., Chaft, J. E., Novello, S., Yang, J., Keller, S. M., Samkari, A., & Spicer, J. D.
Affiliations: Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
From Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA (H.W.); Centre Hospitalier de l’Université de Montréal (M.L.) and McGill University Health Centre (J.D.S.) — both in Montreal; Kanagawa Cancer Center, Yokohama (T.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) — both in Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.-H.L.); the National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (S.G.), and Beijing Cancer Hospital, Peking University (K.-N.C.) — both in Beijing; University Hospitals Leuven, Leuven, Belgium (C.D.); Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas (D.R.-A.) — both in Spain; Zentralklinik Bad Berka, Bad Berka, Germany (E.E.); Sanatorio Parque, Cordoba, Argentina (G.L.M.); Hôpital d’I...
Memorial Sloan Kettering Cancer Center (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
ORCID: Wakelee, Heather
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe
Majem, Margarita
Bylicki, Olivier
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Spicer, Jonathan D.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2023-08-10
Volume: 389
Issue: 6
Pages: 491-503
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2302983
PMC: PMC11074923
OpenAlex: W4379209546
Cited by: 1,180
References: 18
Citations by year: 2026: 324 · 2025: 388 · 2024: 368 · 2023: 100
FWCI: 216.63
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Acceda (Universidad de Las Palmas de Gran Canaria) (submittedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Lirias (KU Leuven) (submittedVersion)
Funders: Merck Sharp and Dohme LLC, a subsidiary of Merck & Co, Inc
National Cancer Institute (P30 CA008748)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pembrolizumab, early-stage non-small cell lung cancer, perioperative immunotherapy, PD-1 inhibitors, cisplatin-based chemotherapy, event-free survival, overall survival, pathological response, pathological complete response, N2 disease, resectable lung cancer, treatment safety, immune-related adverse events
MeSH terms: Adjuvants, Immunologic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Combined Modality Therapy, Humans, Lung Neoplasms, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks